Acceptance and Efficacy of Live Supervision

January 19, 2015 updated by: Florian Weck, Goethe University

Live Supervision Put to Test - Studies of Acceptance and Efficacy of Computer-assisted Live Supervision

In order to meet an existing lack of empirical studies in the field of cognitive behavioral therapy supervision, the present randomized controlled trial is aimed at comparing two different types of supervision. This study compares computer-assisted live supervision and delayed video-based supervision regarding efficacy and acceptance among therapists, patients and supervisors. The efficacy of supervision is defined on different levels such as change of psychotherapeutic competence, nondisclosure, self-efficacy, self-awareness of the supervisee as well as therapeutic alliance, supervisory alliance and therapy outcome.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
42

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
    • Hessen
      • Frankfurt, Hessen, Germany, D-60486
        • Department of Clinical Psychology and Psychotherapy of the Wolfgang Goethe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Supervisees

Inclusion Criteria:

  • Having successfully completed the interim audit
  • Having started to treat ambulant patients under supervision

Exclusion Criteria:

-

Patients

Inclusion Criteria:

  • Meeting ICD 10 criteria for a mental disorder
  • Informed consent

Exclusion Criteria:

  • Currently in psychotherapy
  • Suicidal tendency
  • Clinical diagnosis of alcohol or drug addiction, acute schizophrenia, schizoaffective disorder or bipolar disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: Computer-assisted live supervision
Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as "bug-in-the-eye" (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to.
Behavioral: Computer-assisted live supervision
8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
Other Names:
  • "bug-in-the-eye" (BITE) supervision
  • video-based live supervision
  • monitor-based live supervision
EXPERIMENTAL: Delayed video-based supervision
Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
Behavioral: Delayed video-based supervision
12 video-based sessions (each 50 minutes) during treatment of 2 patients
Other Names:
  • videotape supervision

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Supervisory Questionnaire (SQ)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses nondisclosure of the supervisee during supervision
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Supervisee Levels Questionnaire (SLQ-R)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses self awareness, motivation and dependency- autonomy of supervisees
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Counseling Self-Estimate Inventory (COSE)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses self efficacy of the supervisee
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Fragebogen zur Psychotherapie-Supervision Kurzform (FSPT-K)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses level of development and supervision needs of the therapist
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Helping Alliance Questionnaire (HAQ)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses the therapeutic alliance
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Supervisory Working Alliance Inventory (SWAI)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses the supervisory relationship
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Beck-Depression Inventory II (BDI-II)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses depressive symptoms
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Beck Anxiety Inventory II (BAI)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that asessses anxiety symptoms
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Brief Symptom Inventory (BSI)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses aspects of general psychopathology
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Health-related quality of life (SF-12)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses the health-related quality of life
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Client Satisfaction Questionnaire (CSQ8)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses satisfaction with therapy
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Stundenbogen zur Supervisionsbeurteilung (STEP SV)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
self-report measure that assesses satisfaction with supervision
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
Cognitive Therapy Scale (CTS)
Time Frame: participants will be followed for the duration of psychotherapy, an expected average of 30 weeks
clinician-rated measure that assesses psychotherapeutic competencies
participants will be followed for the duration of psychotherapy, an expected average of 30 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Goethe University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Central Institute of Mental Health, Mannheim

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Martin Bohus, MD, Central Institute of Mental Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2012

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2014

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2014

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 12, 2011

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 10, 2012

First Posted (ESTIMATE)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 13, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 21, 2015

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 19, 2015

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • WECK-012

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings